NCT02033239已完成1 期
A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Area under the glucose infusion rate curve
研究概览
简要总结
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 18-64 years (both inclusive) at the time of signing informed consent
- •Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
- •Body mass index 18.5-28.0 kg/m^2 (both inclusive)
排除标准
- •Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
- •Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)
- •Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period
研究组 & 干预措施
FIAsp
Experimental
Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
干预措施: Faster-acting insulin aspart (Drug)
NovoRapid®
Active Comparator
Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
干预措施: insulin aspart (Drug)
结局指标
主要结局
Area under the glucose infusion rate curve
时间窗: From 0 to 12 hours
次要结局
- Maximum observed serum insulin aspart concentration(Within 0 to 12 hours after dosing)
- Area under the serum insulin aspart concentration-time curve(From 0 to 12 hours)
- Maximum glucose infusion rate(Within 0 to 12 hours after dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01590836Novo Nordisk A/S22
终止
1 期
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01467414Novo Nordisk A/S1
已完成
1 期
Comparison of Two NN1250 Formulations in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01076634Novo Nordisk A/S33
已完成
1 期
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01773798Novo Nordisk A/S33
已完成
1 期
Investigation of the Response Relationship of NN5401 in Type 1 DiabeticsDiabetesDiabetes Mellitus, Type 1NCT00993096Novo Nordisk A/S33